Financetoday
financialTelegram

Lilly Raises Sales Outlook Again as Zepbound Demand Surges

Earnings·October 29, 2026

Lilly Raises Sales Outlook Again as Zepbound Demand Surges

Eli Lilly has raised its full-year sales forecast for the third time this year, a sign that demand for its weight-loss drug Zepbound is running ahead of what the company had planned for. Investors reacted quickly, and the drugmaker's shares were rallying on the news.

Zepbound, an injectable treatment for obesity, has been the main driver of the upgrades. It uses the same active ingredient as Lilly's diabetes medicine Mounjaro. Repeated increases to the outlook suggest the growth is not a one-time bump but a steady build in prescriptions.

The results reinforce Lilly's position in the U.S. market for prescription weight-loss drugs, where it remains the dominant player. That lead gives the company a strong base for the rest of the year and for its longer-term obesity pipeline.

For investors, the takeaway is that demand for these treatments is still expanding and Lilly is capturing much of that growth. The key question ahead is whether the pace can hold as competitors bring their own products to market.

Reporting based on an external source.